- Conditions
- Postbariatric Hypoglycemia
- Interventions
- MBX 1416 (INN imapextide)
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Morehead City, North Carolina • Knoxville, Tennessee + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Mizagliflozin
- Drug
- Lead sponsor
- Vogenx, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Aurora, Colorado
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- exendin 9-39, Placebo
- Drug · Other
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Mizagliflozin, Placebo
- Drug
- Lead sponsor
- Vogenx, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Aurora, Colorado